<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00472641</url>
  </required_header>
  <id_info>
    <org_study_id>96972</org_study_id>
    <nct_id>NCT00472641</nct_id>
  </id_info>
  <brief_title>Geodon in Weight Loss Study for Bipolar Disorders</brief_title>
  <official_title>Adjunctive Ziprasidone in Overweight and Obese Patients With Bipolar Disorder</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stanford University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This research study is designed to determine if replacing your current antipsychotic and/or
      mood stabilizer with ziprasidone (Geodon) will impact weight. This research is being
      conducted because Geodon has a documented effect on mood. Additionally, we believe Geodon to
      be an effective medication for overweight or obese patients with bipolar disorder. There will
      be approximately 25 patients enrolled in this study.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2007</start_date>
  <completion_date type="Actual">December 2009</completion_date>
  <primary_completion_date type="Actual">December 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The Primary Outcome Measure Was Weight Change From Baseline to Endpoint.</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>The primary outcome measure will be the change in weight from baseline to endpoint using a random regression mixed effects model.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes From Baseline to Endpoint in Body Mass Index (BMI)</measure>
    <time_frame>Baseline, 12 weeks</time_frame>
    <description>Secondary outcome measures will include the change from baseline to endpoint in Body Mass Index (BMI).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">25</enrollment>
  <condition>Bipolar Disorder</condition>
  <arm_group>
    <arm_group_label>Ziprasidone/Geodon</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ziprasidone/Geodon up to 320 mg per day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ziprasidone/Geodon</intervention_name>
    <description>Ziprasidone/Geodon</description>
    <arm_group_label>Ziprasidone/Geodon</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:Patients will meet the following criteria to be eligible to participate
        in the study:

          -  Diagnosis of Bipolar Disorder Type I, Type II, or NOS treated in ongoing therapy with
             atypical antipsychotic(s) and/or mood stabilizer(s) that have been implicated in
             causing weight gain (i.e. lithium, valproate, olanzapine, risperidone, quetiapine,
             aripiprazole).

          -  Age 18-65 years old

          -  Males; or nonpregnant, nonlactating females who are postmenopausal, surgically
             sterilized, or using a barrier method of contraception and have a negative pregnancy
             test

          -  Initial body mass index e 30 kg/m2, or e 27 kg/m2 and demonstrating or receiving
             treatment for metabolic consequences of overweight (fasting total cholesterol e
             200mg/dL, fasting triglycerides e 250 mg/dL, or fasting blood glucose e 100 mg/dL).

          -  Stable medication regimen of at least one month

          -  Not have been hospitalized due to medical or psychiatric reasons during the past year
             from date of consent.

          -  Ability to understand and cooperate with study procedures

          -  Have signed a written informed consent prior to entering the study Exclusion
             Criteria:Patients may not participate in the study if they have any of the following
             conditions:

          -  One of the following DSM-IV Axis I diagnoses: delirium, dementia, amnestic and other
             cognitive disorders, schizophrenia, anorexia nervosa or bulimia, or substance abuse or
             dependence (active within the last month), abuse of illicit drugs (excluding
             marijuana) within the past month

          -  Antisocial personality disorder

          -  Medical complications of obesity such as diabetes, hypertension, hyperlipidemia, and
             cardiovascular disease unless followed by their own general medical practitioner who
             authorizes their participation in the trial, and continues to follow them medically
             and make necessary adjustments of concurrent antidiabetic, antihypertensive,
             antihyperlipidemic agents during the trial;

          -  Item 10 (Suicidal Thoughts) on the MADRS greater than or equal to 4

          -  Suicide attempt within the past three months

          -  Obesity of endocrine origin

          -  Seizure disorders

          -  Progressive neurologic or systemic disorders; HIV

          -  Other serious illnesses such as cardiac, hepatic (including cirrhosis), renal,
             respiratory, neurologic, or hematologic disease or glaucoma

          -  Hypothyroidism or hyperthyroidism unless adequately treated with TSH no more than 10%
             above or below the limits of the normal range.

          -  Administration of any investigational drug within 30 days prior to screening

          -  Allergy or hypersensitivity to ziprasidone

          -  Administration of clozapine in the prior three months

          -  Pregnancy within the past six months

          -  Patients will be discontinued from the study should they develop any significant
             adverse side effects that cannot be managed by dosage adjustment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Terence Arthur Ketter</last_name>
    <role>Principal Investigator</role>
    <affiliation>Stanford University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Stanford University School of Medicine</name>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <zip>94305</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.bipolar.org</url>
    <description>Stanford University Bipolar Disorders Clinic</description>
  </link>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 11, 2007</study_first_submitted>
  <study_first_submitted_qc>May 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 14, 2007</study_first_posted>
  <results_first_submitted>December 9, 2016</results_first_submitted>
  <results_first_submitted_qc>March 29, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">May 9, 2017</results_first_posted>
  <last_update_submitted>March 29, 2017</last_update_submitted>
  <last_update_submitted_qc>March 29, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">May 9, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Terrence Ketter</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Disease</mesh_term>
    <mesh_term>Bipolar Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ziprasidone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Ziprasidone/Geodon</title>
          <description>Ziprasidone/Geodon up to 320 mg per day
Ziprasidone/Geodon: Ziprasidone/Geodon</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="25"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lack of Efficacy</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Ziprasidone/Geodon</title>
          <description>Ziprasidone/Geodon up to 320 mg per day
Ziprasidone/Geodon: Ziprasidone/Geodon</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="25"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="46.8" spread="11.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Bipolar Subtype</title>
          <description>Bipolar I is characterized by one or more manic episodes or mixed episodes. Typically a person will experience periods of depression as well. Bipolar I disorder is marked by manic episodes. Bipolar II disorder is diagnosed after one or more major depressive episodes and at least one episode of hypomania, with possible periods of level mood between episodes.
Bipolar disorder that does not follow a particular pattern is called bipolar disorder Not Otherwise Specified (NOS).
Diagnosis follows criteria put forth by the DSM-4</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Bipolar 1</title>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Bipolar 2</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Bipolar NOS</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>pounds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="205.2" spread="31.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32.9" spread="3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Waist Circumference</title>
          <units>inches</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41.7" spread="4.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>The Primary Outcome Measure Was Weight Change From Baseline to Endpoint.</title>
        <description>The primary outcome measure will be the change in weight from baseline to endpoint using a random regression mixed effects model.</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone/Geodon</title>
            <description>Ziprasidone/Geodon up to 320 mg per day
Ziprasidone/Geodon: Ziprasidone/Geodon</description>
          </group>
        </group_list>
        <measure>
          <title>The Primary Outcome Measure Was Weight Change From Baseline to Endpoint.</title>
          <description>The primary outcome measure will be the change in weight from baseline to endpoint using a random regression mixed effects model.</description>
          <units>Pounds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.8" spread="7.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.00001</p_value>
            <method>Random Regression Mixed Effects Modeling</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Changes From Baseline to Endpoint in Body Mass Index (BMI)</title>
        <description>Secondary outcome measures will include the change from baseline to endpoint in Body Mass Index (BMI).</description>
        <time_frame>Baseline, 12 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Ziprasidone/Geodon</title>
            <description>Ziprasidone/Geodon up to 320 mg per day
Ziprasidone/Geodon: Ziprasidone/Geodon</description>
          </group>
        </group_list>
        <measure>
          <title>Changes From Baseline to Endpoint in Body Mass Index (BMI)</title>
          <description>Secondary outcome measures will include the change from baseline to endpoint in Body Mass Index (BMI).</description>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>&lt;0.00001</p_value>
            <method>Random Regression Mixed Effects Modeling</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Ziprasidone/Geodon</title>
          <description>Ziprasidone/Geodon up to 320 mg per day
Ziprasidone/Geodon: Ziprasidone/Geodon</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Viral Gastroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Hypomania</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Loss of Consciousness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="25"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>The current study has noteworthy limitations, including a small sample size, short trial duration, and an open, uncontrolled design.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Po W. Wang</name_or_title>
      <organization>Stanford University School of Medicine</organization>
      <phone>650-723-2483</phone>
      <email>wangp0@stanford.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

